scholarly journals Mucosal Vaccine Development Based on Liposome Technology

2016 ◽  
Vol 2016 ◽  
pp. 1-16 ◽  
Author(s):  
Valentina Bernasconi ◽  
Karin Norling ◽  
Marta Bally ◽  
Fredrik Höök ◽  
Nils Y. Lycke
Keyword(s):  
Immune Responses ◽  
Protective Immunity ◽  
Recent Progress ◽  
Vaccine Development ◽  
Mucosal Vaccine ◽  
Limiting Factor ◽  
Successful Development ◽  
Mucosal Vaccines ◽  
Increasing Demand ◽  
Portal Of Entry

Immune protection against infectious diseases is most effective if located at the portal of entry of the pathogen. Hence, there is an increasing demand for vaccine formulations that can induce strong protective immunity following oral, respiratory, or genital tract administration. At present, only few mucosal vaccines are found on the market, but recent technological advancements and a better understanding of the principles that govern priming of mucosal immune responses have contributed to a more optimistic view on the future of mucosal vaccines. Compared to live attenuated vaccines, subcomponent vaccines, most often protein-based, are considered safer, more stable, and less complicated to manufacture, but they require the addition of nontoxic and clinically safe adjuvants to be effective. In addition, another limiting factor is the large antigen dose that usually is required for mucosal vaccines. Therefore, the combination of mucosal adjuvants with the recent progress in nanoparticle technology provides an attractive solution to these problems. In particular, the liposome technology is ideal for combining protein antigen and adjuvant into an effective mucosal vaccine. Here, we describe and discuss recent progress in nanoparticle formulations using various types of liposomes that convey strong promise for the successful development of the next generation of mucosal vaccines.

scholarly journals Interleukin-1 Family Cytokines as Mucosal Vaccine Adjuvants for Induction of Protective Immunity against Influenza Virus

2010 ◽  
Vol 84 (24) ◽  
pp. 12703-12712 ◽  
Author(s):  
Hiroyuki Kayamuro ◽  
Yasuo Yoshioka ◽  
Yasuhiro Abe ◽  
Shuhei Arita ◽  
Kazufumi Katayama ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Immune Responses ◽  
Interleukin 1 ◽  
Influenza Virus Infection ◽  
Mucosal Vaccine ◽  
Vaccine Adjuvants ◽  
Mucosal Surfaces ◽  
Mucosal Vaccines ◽  
Etiological Agents ◽  
Family Cytokine

ABSTRACT A safe and potent adjuvant is needed for development of mucosal vaccines against etiological agents, such as influenza virus, that enter the host at mucosal surfaces. Cytokines are potential adjuvants for mucosal vaccines because they can enhance primary and memory immune responses enough to protect against some infectious agents. For this study, we tested 26 interleukin (IL) cytokines as mucosal vaccine adjuvants and compared their abilities to induce antigen (Ag)-specific immune responses against influenza virus. In mice intranasally immunized with recombinant influenza virus hemagglutinin (rHA) plus one of the IL cytokines, IL-1 family cytokines (i.e., IL-1α, IL-1β, IL-18, and IL-33) were found to increase Ag-specific immunoglobulin G (IgG) in plasma and IgA in mucosal secretions compared to those after immunization with rHA alone. In addition, high levels of both Th1- and Th2-type cytokines were observed in mice immunized with rHA plus an IL-1 family cytokine. Furthermore, mice intranasally immunized with rHA plus an IL-1 family cytokine had significant protection against a lethal influenza virus infection. Interestingly, the adjuvant effects of IL-18 and IL-33 were significantly decreased in mast cell-deficient W/W v mice, indicating that mast cells have an important role in induction of Ag-specific mucosal immune responses induced by IL-1 family cytokines. In summary, our results demonstrate that IL-1 family cytokines are potential mucosal vaccine adjuvants and can induce Ag-specific immune responses for protection against pathogens like influenza virus.

scholarly journals Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV

Viruses ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1871
Author(s):  
Naglaa H. Shoukry
Keyword(s):  
Systems Biology ◽  
Protective Immunity ◽  
Recent Progress ◽  
Viral Infections ◽  
Vaccine Development ◽  
Immune Functions ◽  
The Past ◽  
Systems Immunology ◽  
Tremendous Progress ◽  
Made In

Over the past decade, tremendous progress has been made in systems biology-based approaches to studying immunity to viral infections and responses to vaccines. These approaches that integrate multiple facets of the immune response, including transcriptomics, serology and immune functions, are now being applied to understand correlates of protective immunity against hepatitis C virus (HCV) infection and to inform vaccine development. This review focuses on recent progress in understanding immunity to HCV using systems biology, specifically transcriptomic and epigenetic studies. It also examines proposed strategies moving forward towards an integrated systems immunology approach for predicting and evaluating the efficacy of the next generation of HCV vaccines.

scholarly journals Analysis of the Role of TpUB05 Antigen from Theileria parva in Immune Responses to Malaria in Humans Compared to Its Homologue in Plasmodium falciparum the UB05 Antigen

Pathogens ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 271
Author(s):  
Jerome Nyhalah Dinga ◽  
Stephanie Numenyi Perimbie ◽  
Stanley Dobgima Gamua ◽  
Francis N. G. Chuma ◽  
Dieudonné Lemuh Njimoh ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Immune Responses ◽  
Protective Immunity ◽  
Vaccine Development ◽  
Theileria Parva ◽  
Peripheral Blood Mononuclear ◽  
Significant Difference ◽  
First Time

Despite the amount of resources deployed and the technological advancements in molecular biology, vaccinology, immunology, genetics, and biotechnology, there are still no effective vaccines against malaria. Immunity to malaria is usually seen to be species- and/or strain-specific. However, there is a growing body of evidence suggesting the possibility of the existence of cross-strain, cross-species, and cross-genus immune responses in apicomplexans. The principle of gene conservation indicates that homologues play a similar role in closely related organisms. The homologue of UB05 in Theileria parva is TpUB05 (XP_763711.1), which has been tested and shown to be associated with protective immunity in East Coast fever. In a bid to identify potent markers of protective immunity to aid malaria vaccine development, TpUB05 was tested in malaria caused by Plasmodium falciparum. It was observed that TpUB05 was better at detecting antigen-specific antibodies in plasma compared to UB05 when tested by ELISA. The total IgG raised against TpUB05 was able to block parasitic growth in vitro more effectively than that raised against UB05. However, there was no significant difference between the two study antigens in recalling peripheral blood mononuclear cell (PBMC) memory through IFN-γ production. This study suggests, for the first time, that TpUB05 from T. parva cross-reacts with UB05 from P. falciparum and is a marker of protective immunity in malaria. Hence, TpUB05 should be considered for possible development as a potential subunit vaccine candidate against malaria.

Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1

2011 ◽  
Vol 57 (3) ◽  
pp. 256-261 ◽  
Author(s):  
Belkis Romeu ◽  
Elyzabeth González ◽  
Judith del Campo ◽  
Reynaldo Acevedo ◽  
Caridad Zayas ◽  
...  
Keyword(s):  
Immune Responses ◽  
Tetanus Toxoid ◽  
Mucosal Vaccine ◽  
Vaccine Adjuvants ◽  
Mucosal Adjuvant ◽  
Mucosal Vaccines ◽  
Nasal Immunization ◽  
Human Use ◽  
Vaginal Wash ◽  
Systemic Compartment

Mucosal immune responses are an early and important line of defense against pathogens. The current understanding of the mucosal immune system allows us to consider the use of nasal immunization for induction of antigen-specific immune responses at the mucosal surface and the systemic compartment. Mucosal adjuvants are key for developing novel mucosal vaccines and represent 1 approach to improving mucosal and systemic immunity. However, few mucosal vaccine adjuvants are currently approved for human use. Neisseria meningitidis B proteoliposome-derived cochleate (AFCo1 — Adjuvant Finlay Cochleate 1) has been demonstrated to be a potent mucosal adjuvant. The present work demonstrates that intranasal immunization of 3 doses of tetanus toxoid (TT) coadministered with AFCo1 in mice promotes high systemic and mucosal responses. The anti-TT IgG serum titers and the mucosal anti-TT IgA in saliva and vaginal wash were significantly higher than TT alone. The analysis of antibody subclasses showed that intranasal administration of AFCo1 + TT induced not only IgG1 but also IgG2a anti-TT antibodies at levels comparable to those obtained with TT vaccine (vax-TET). These data support the fact that AFCo1 is a potent mucosal adjuvant in nasal immunization to a coadministered protein antigen.

scholarly journals Vaccines against enteric infections for the developing world

2015 ◽  
Vol 370 (1671) ◽  
pp. 20150142 ◽  
Author(s):  
Cecil Czerkinsky ◽  
Jan Holmgren
Keyword(s):  
Vaccine Development ◽  
Oral Vaccine ◽  
Herd Immunity ◽  
Oral Polio Vaccine ◽  
Developed Countries ◽  
Mucosal Vaccine ◽  
List Type ◽  
Limited Knowledge ◽  
Enteric Infections ◽  
Mucosal Vaccines

Since the first licensure of the Sabin oral polio vaccine more than 50 years ago, only eight enteric vaccines have been licensed for four disease indications, and all are given orally. While mucosal vaccines offer programmatically attractive tools for facilitating vaccine deployment, their development remains hampered by several factors: — limited knowledge regarding the properties of the gut immune system during early life; — lack of mucosal adjuvants, limiting mucosal vaccine development to live-attenuated or killed whole virus and bacterial vaccines; — lack of correlates/surrogates of mucosal immune protection; and — limited knowledge of the factors contributing to oral vaccine underperformance in children from developing countries. There are now reasons to believe that the development of safe and effective mucosal adjuvants and of programmatically sound intervention strategies could enhance the efficacy of current and next-generation enteric vaccines, especially in lesser developed countries which are often co-endemic for enteric infections and malnutrition. These vaccines must be safe and affordable for the world's poorest, confer long-term protection and herd immunity, and must be able to contain epidemics.

scholarly journals Oral Immunization with RecombinantStreptococcus gordonii Expressing Porphyromonas gingivalis FimA Domains

2001 ◽  
Vol 69 (5) ◽  
pp. 2928-2934 ◽  
Author(s):  
Ashu Sharma ◽  
Kiyonobu Honma ◽  
Richard T. Evans ◽  
Dennis E. Hruby ◽  
Robert J. Genco
Keyword(s):  
Bone Loss ◽  
Immune Responses ◽  
Porphyromonas Gingivalis ◽  
Oral Delivery ◽  
Alveolar Bone ◽  
Vaccine Development ◽  
Alveolar Bone Loss ◽  
Biologically Active ◽  
Mucosal Vaccine ◽  
Critical Surface

ABSTRACT Porphyromonas gingivalis, a gram-negative anaerobe, is implicated in the etiology of adult periodontitis. P. gingivalis fimbriae are one of several critical surface virulence factors involved in both bacterial adherence and inflammation. P. gingivalis fimbrillin (FimA), the major subunit protein of fimbriae, is considered an important antigen for vaccine development against P. gingivalis-associated periodontitis. We have previously shown that biologically active domains of P. gingivalis fimbrillin can be expressed on the surface of the human commensal bacterium Streptococcus gordonii. In this study, we examined the effects of oral coimmunization of germfree rats with two S. gordonii recombinants expressing N (residues 55 to 145)- and C (residues 226 to 337)-terminal epitopes of P. gingivalis FimA to elicit FimA-specific immune responses. The effectiveness of immunization in protecting against alveolar bone loss following P. gingivalis infection was also evaluated. The results of this study show that the oral delivery of P. gingivalis FimA epitopes via S. gordonii vectors resulted in the induction of FimA-specific serum (immunoglobulin G [IgG] and IgA) and salivary (IgA) antibody responses and that the immune responses were protective against subsequent P. gingivalis-induced alveolar bone loss. These results support the potential usefulness of the S. gordonii vectors expressingP. gingivalis fimbrillin as a mucosal vaccine against adult periodontitis.

scholarly journals T Lymphocyte Immunity in Host Defence againstChlamydia trachomatisand Its Implication for Vaccine Development

1998 ◽  
Vol 9 (2) ◽  
pp. 99-109 ◽  
Author(s):  
X Yang ◽  
RC Brunham
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Protective Immunity ◽  
Vaccine Development ◽  
Research Effort ◽  
Dominant Role ◽  
Bacterial Pathogen ◽  
Cd4 T Cell ◽  
T Helper 1 ◽  
Humoral Immune

Chlamydia trachomatisis an obligate intracellular bacterial pathogen that causes several significant human infectious diseases, including trachoma, urethritis, cervicitis and salpingitis, and is an important cofactor for transmission of human immunodeficiency virus. Until very recently, over three decades of research effort aimed at developing aC trachomatisvaccine had failed, due mainly to the lack of a precise understanding of the mechanisms for protective immunity. Although most studies concerning protective immunity toC trachomatishave focused on humoral immune responses, recent studies have clearly shown that T helper-1 (Th1)-like CD4 T cell-mediated immune responses play the dominant role in protective immunity. These studies suggest a paradigm for chlamydial immunity and pathology based on the concept of heterogeneity (Th1/Th2) in CD4 T cell immune responses. This concept for chlamydial immunity offers a rational template on which to base renewed efforts for development of a chlamydial vaccine that targets the induction of cell-mediated Th1 immune responses.

scholarly journals Analysis of the role of TpUB05 antigen from Theileria parva in immune responses to malaria in humans compared to its homologue in Plasmodium falciparum; UB05 antigen

2019 ◽  
Author(s):  
Jerome Nyhalah Dinga ◽  
Stanley Dobgima Gamua ◽  
Stephanie Numenyi Perimbie ◽  
Francis N. G. Chuma ◽  
Dieudonné Lemuh Njimoh ◽  
...  
Keyword(s):  
Immune Responses ◽  
Protective Immunity ◽  
Vaccine Development ◽  
Ex Vivo ◽  
Growth Inhibition Assay ◽  
Potential Marker ◽  
As Species ◽  
Potential Vaccine ◽  
First Time

Abstract Background: Despite the amount of resources deployed and technological advancements in Molecular Biology, vaccinology, immunology, genetics, and biotechnology, there is still no effective vaccines against malaria. Immunity to either malaria or East Coast fever is usually seen as species- and/or strain-specific. But there is growing body of evidence suggesting the possibility of the existence of cross strain, cross species and cross genus immune responses in apicomplexans. The principle of gene conservations indicates that homologues play similar role in closely related organisms. UB05 antigen (XP_001347656.2) from P. falciparum is part of chimeric UB05-09 antigen; a potential vaccine candidate has been demonstrated to be a marker of protective immunity in malaria. The homologue of UB05 in T. parva is TpUB05 (XP_763711.1) which was also tested and shown to be a potential marker of protective immunity in ECF as well. In a bid to identify potent markers of protective immunity to aid malaria vaccine development, TpUB05 was tested in malaria caused by P. falciparum . Results: It was observed that TpUB05 provoked stronger immune responses in malaria compared to UB05 antigen as tested using ELISA, ex-vivo ELISpot assay and in vitro growth inhibition assay. Conclusion: This study suggests for the first time that TpUB05 from T. parva is a better marker of protective immunity in malaria compared to its homologue UB05 from P. falciparum .

scholarly journals Analysis of the role of TpUB05 antigen from Theileria parva in immune responses to malaria in humans compared to its homologue in Plasmodium falciparum; UB05 antigen

2019 ◽  
Author(s):  
Jerome Nyhalah Dinga ◽  
Stanley Dobgima Gamua ◽  
Dieudonné Lemuh Njimoh ◽  
Francis N. G. Chuma ◽  
Apollinaire Djikeng ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Immune Responses ◽  
Protective Immunity ◽  
Vaccine Development ◽  
Ex Vivo ◽  
Theileria Parva ◽  
Endemic Region ◽  
Experimental Conditions ◽  
Potential Marker ◽  
As Species

Abstract Despite the amount of resources deployed and technological advancements in Molecular Biology, vaccinology, immunology, genetics, and biotechnology, there is still no effective vaccines against malaria. Immunity to either malaria or East Coast fever is usually seen as species- and/or strain-specific. But there is growing body of evidence suggesting the possibility of the existence of cross strain, cross species and cross genus immune responses in apicomplexans. The principle of gene conservations indicates that homologues play similar role in closely related organisms. UB05 antigen (XP_001347656.2) from Plasmodium falciparum is part of chimeric UB05-09 antigen; a potential vaccine candidate has been demonstrated to be a marker of protective immunity in malaria. The homologue of UB05 in Theileria parva is TpUB05 (XP_763711.1) which was also tested and shown to be a potential marker of protective immunity in ECF as well. In a bid to identify potent markers of protective immunity to aid malaria vaccine development, TpUB05 was tested in malaria caused by Plasmodium falciparum . UB05 antigen was tested in malaria using ELISpot, ELISA, and Growth Inhibition assays with samples from a malaria endemic region, and published. During these same experiments, TpUB05 antigen was tested alongside UB05, in separate wells but on the same plates and exposed to the same experimental conditions and the result presented here. Here we compare the performance of TpUB05 to that of UB05 in terms of the type and magnitude of immune responses provoked in malaria. It was observed that TpUB05 provoked stronger immune responses in malaria compared to UB05 antigen ex-vivo . This suggests that TpUB05 from Theileria parva is a better marker of protective immunity in malaria compared to its homologue UB05 from Plasmodium falciparum .

Sign in / Sign up

Export Citation Format

Share Document